A5054423993- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Genetics and Neurodevelopmental Disorders
- Genomics and Rare Diseases
- Family and Disability Support Research
- EEG and Brain-Computer Interfaces
- Diet and metabolism studies
- Attention Deficit Hyperactivity Disorder
- Functional Brain Connectivity Studies
- Drug Transport and Resistance Mechanisms
- Machine Learning in Healthcare
- Metabolism and Genetic Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Infectious Encephalopathies and Encephalitis
- Neuroscience and Neuropharmacology Research
- Delphi Technique in Research
- Nursing Roles and Practices
- Hip and Femur Fractures
- Chronic Disease Management Strategies
- Digital Mental Health Interventions
- Cerebral Palsy and Movement Disorders
- Thermal Regulation in Medicine
- Dental Education, Practice, Research
- Clinical Reasoning and Diagnostic Skills
- Workplace Violence and Bullying
The Royal Wolverhampton NHS Trust
2017-2025
University of Wolverhampton
2021-2024
Epilepsy Action
2024
National Health Service
2024
Cannock Chase Hospital
2022
University Hospital of Wales
2021
Stafford College
2013-2014
University Hospitals of North Midlands NHS Trust
2007
Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not women of child-bearing potential because teratogenicity. Levetiracetam increasingly prescribed these patient populations despite scarcity evidence clinical effectiveness cost-effectiveness. We aimed compare the long-term and cost-effectiveness levetiracetam compared valproate in participants unclassifiable epilepsy.We did an open-label, randomised controlled...
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty to whether they should be recommended first-line treatments because of insufficient evidence clinical effectiveness cost-effectiveness. We aimed assess the long-term cost-effectiveness levetiracetam compared lamotrigine in people newly diagnosed epilepsy.This randomised, open-label, controlled trial treatment epilepsy. Adult paediatric neurology services across UK recruited...
In England, nearly a quarter of people with intellectual disability (PwID) have epilepsy. Though 70 % PwID pharmaco-resistant seizures only 10 are prescribed anti-seizure medication (ASMs) licenced for pharmaco-resistance. Brivaracetam (BRV) in 2016 has had nine post-marketing studies involving PwID. These limited either by lack controls or not looking at outcomes based on differing levels ID severity. This study looks evidence comparing effectiveness and side-effects to those without (BRV).
Abstract Objective This study was undertaken to validate a set of candidate biomarkers seizure susceptibility in retrospective, multisite case–control study, and determine the robustness these derived from routinely collected electroencephalography (EEG) within large cohort (both epilepsy common alternative conditions such as nonepileptic attack disorder). Methods The database consisted 814 EEG recordings 648 subjects, eight National Health Service sites across UK. Clinically noncontributory...
A Core Outcome Set (COS) is a standardised list of outcomes that should be reported as minimum in all clinical trials. In epilepsy, the choice varies widely among existing studies, particularly This diminishes opportunities for informed decision-making, contributes to research waste and barrier integrating findings systematic reviews meta-analyses. Furthermore, currently being measured may not reflect what important people with epilepsy. Therefore, we aim develop COS specific effectiveness...
Epilepsy prevalence is significantly higher in people with Intellectual Disability (ID) compared to epilepsy (PWE) from the general population. Increased psychological and behavioural problems, healthcare costs, morbidity, mortality treatment resistance antiepileptic drugs (AEDs) associated ID populations. Prescribing AEDs for PWE challenging influenced heavily by studies conducted Our study compares Lacosamide (LCM) response population those population; using data an UK based database...
BackgroundPsychiatric and behavioral side effects (PBSEs) are a major cause of antiepileptic drug (AED) withdrawal. Levetiracetam (LEV) is recognized first-line AED with good seizure outcomes but PBSEs. Eslicarbazepine (ESL) considered to function similarly an active metabolite the commonly used carbamazepine (CBZ). Carbamazepine as psychotropic medication assist in various psychiatric illnesses such mood disorders, aggression, anxiety.AimThe aim was evaluate profile ESL people who had LEV...
Nearly a quarter of people with intellectual disability (ID) have epilepsy large numbers experiencing drug-resistant epilepsy, and premature mortality. To mitigate risks the environment social care needs, particularly in professional settings, need to be met.To compare groups as regards their subjective confidence perceived responsibility when managing ID epilepsy.A multi-agency expert panel developed questionnaire embedded case vignettes quantitative qualitative elements understand training...
People with intellectual disability (PwID) and epilepsy have increased premature potentially preventable mortality. This is related to a lack of equitable access appropriate care. The Step Together guidance toolkit, developed patient, clinical, charity commissioning stakeholders, allows evaluation benchmarking essential service provision for PwID in eight key domains, at care system level.
Background A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for safe and effective prescribing antiepileptic drugs (AEDs) those ID is, however, limited. Aims Study This study seeks strengthen research evidence around Eslicarbazepine Acetate (ESL), new AED, by comparing response individuals from population who do not ID. Methods single data set was created through retrospective collection...
Valproate (VPA) is an effective treatment for epilepsy and also used in bipolar disorder. However, VPA associated with a significant risk of birth defects developmental disorders if during pregnancy. This has led to the introduction measures reduce use valproate women childbearing potential such as 'Prevent' pregnancy prevention program (PPP) completion annual acknowledgement form (ARAF). The aim current audit was assess compliance guidance. An tool made available neurologists registered...
There is a demand across the country for highly trained epilepsy specialist nurses (ESNs) due to increasing number of patients that this long-term condition affects. It estimated 65 million people worldwide are affected by epilepsy. If not treated and supported effectively, comes with high risk mortality, comorbidities, stigma potential costs NHS. Patients who do have access ESNs can be significantly negatively wrong diagnosis, gaps in knowledge when facing general care, incorrect and, on...
Artificial intelligence (AI) and machine learning (ML) are increasingly being used in medicine. More recently, both AI ML have been applied epilepsy research, with the aim of accurately predicting detecting seizures. Most AL applications need to undergo trials ensure that accurate data captured. The following article discusses such systems which currently developed for patients, have/are undergoing patient trials.
Summary Recent studies using computational and mathematical interrogation of background EEG have revealed eight biomarkers that inform a diagnostic decision-support tool called BioEP. To assess the utility BioEP for aiding clinical decision making, we conducted prospective single-site belief updating study ( NCT05764252 ). Eighty-six adults with suspected seizures attended nurse-led, first-seizure clinic. Using 7-point scale ranging from ‘virtually certain’ to ‘exceptionally unlikely’, two...
Background Epilepsy is a chronic neurological disorder affecting individuals globally, marked by recurrent and apparently unpredictable seizures that pose significant challenges, including increased mortality, injuries, diminished quality of life. Despite advancements in treatments, proportion people with epilepsy continue to experience uncontrolled seizures. The apparent unpredictability these events has been identified as major concern for epilepsy, highlighting the need innovative seizure...
<sec> <title>BACKGROUND</title> Epilepsy is a chronic neurological disorder affecting individuals globally, marked by recurrent and apparently unpredictable seizures that pose significant challenges, including increased mortality, injuries, diminished quality of life. Despite advancements in treatments, proportion people with epilepsy continue to experience uncontrolled seizures. The apparent unpredictability these events has been identified as major concern for epilepsy, highlighting the...
<h3>Purpose</h3> We report on the safety and efficacy of eslicarbazepine acetate (ESL) in routine clinical practice. <h3>Method</h3> Retrospective multicentre audit outcomes following ESL treatment for localisation-related epilepsy across 7 UK sites (2009–2013). <h3>Results</h3> 201 patients with median values age 43.0 (18–83) years; duration 17.0 (0–65) 2 (0–4) concomitant AEDs, 12 months (2 days-53 months) 0–12 (87.1% ≥2) previous AED exposures. dosage ranged from 400–1600 mg/day. Baseline...